|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0035020,
umls-concept:C0085862,
umls-concept:C0152254,
umls-concept:C0205466,
umls-concept:C0439831,
umls-concept:C0871261,
umls-concept:C1299583,
umls-concept:C1533728,
umls-concept:C1549571,
umls-concept:C1608386,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2698872,
umls-concept:C2911692
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-7-25
|
|
pubmed:abstractText |
It is recommended that patients with chronic hepatitis C virus (HCV) genotype 3 infections receive 24 weeks of treatment. A rapid virologic response (RVR; at week 4) predicts a sustained virologic response (SVR), although not all patients with an RVR achieve an SVR. We explored the relationships among hepatic steatosis, level of HCV RNA, relapse, and RVR in a phase 3 randomized controlled trial of 932 patients infected with HCV genotype 2 (n = 427) or 3 (n = 505) who received 24 weeks of therapy with interferon-?.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1542-7714
|
|
pubmed:author |
pubmed-author:FosterGraham RGR,
pubmed-author:HealeyLethaL,
pubmed-author:KottililShyamS,
pubmed-author:MannsMichaelM,
pubmed-author:MarcellinPatrickP,
pubmed-author:McHutchisonJohn GJG,
pubmed-author:NelsonDavid RDR,
pubmed-author:PatelKeyurK,
pubmed-author:PulkstenisErikE,
pubmed-author:ShahSamir RSR,
pubmed-author:SubramanianG ManiGM,
pubmed-author:SulkowskiMark SMS,
pubmed-author:ZeuzemStefanS
|
|
pubmed:copyrightInfo |
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
688-93
|
|
pubmed:meshHeading |
pubmed-meshheading:21640198-Adult,
pubmed-meshheading:21640198-Alanine Transaminase,
pubmed-meshheading:21640198-Antiviral Agents,
pubmed-meshheading:21640198-Fatty Liver,
pubmed-meshheading:21640198-Female,
pubmed-meshheading:21640198-Genotype,
pubmed-meshheading:21640198-Hepacivirus,
pubmed-meshheading:21640198-Hepatitis C, Chronic,
pubmed-meshheading:21640198-Humans,
pubmed-meshheading:21640198-Interferon-alpha,
pubmed-meshheading:21640198-Liver Cirrhosis,
pubmed-meshheading:21640198-Male,
pubmed-meshheading:21640198-Middle Aged,
pubmed-meshheading:21640198-Prognosis,
pubmed-meshheading:21640198-RNA, Viral,
pubmed-meshheading:21640198-Recurrence,
pubmed-meshheading:21640198-Treatment Failure,
pubmed-meshheading:21640198-Viral Load,
pubmed-meshheading:21640198-gamma-Glutamyltransferase
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.
|
|
pubmed:affiliation |
Department of Gastroenterology, Jaslok Hospital, Mumbai, India.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
